464.93 USD
-7.06 (-1.5%)
464.93 USD
0 (0%)
Taking everything into account, UTHR scores 7 out of 10 in our fundamental rating. UTHR was compared to 528 industry peers in the Biotechnology industry. UTHR gets an excellent profitability rating and is at the same time showing great financial health properties. UTHR is not valued too expensively and it also shows a decent growth rate. This makes UTHR very considerable for quality investing!
1. Profitability
1.1 Basic Checks
- In the past year UTHR was profitable.
- UTHR had a positive operating cash flow in the past year.
- UTHR had positive earnings in each of the past 5 years.
- UTHR had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- The Return On Assets of UTHR (17.30%) is better than 96.02% of its industry peers.
- Looking at the Return On Equity, with a value of 19.30%, UTHR belongs to the top of the industry, outperforming 95.64% of the companies in the same industry.
- UTHR has a Return On Invested Capital of 17.33%. This is amongst the best in the industry. UTHR outperforms 96.97% of its industry peers.
- UTHR had an Average Return On Invested Capital over the past 3 years of 14.96%. This is below the industry average of 18.28%.
- The 3 year average ROIC (14.96%) for UTHR is below the current ROIC(17.33%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.3% | ||
| ROE | 19.3% | ||
| ROIC | 17.33% |
ROA(3y)14%
ROA(5y)12.47%
ROE(3y)16.72%
ROE(5y)15.47%
ROIC(3y)14.96%
ROIC(5y)13.31%
1.3 Margins
- The Profit Margin of UTHR (40.65%) is better than 96.97% of its industry peers.
- In the last couple of years the Profit Margin of UTHR has grown nicely.
- UTHR's Operating Margin of 48.65% is amongst the best of the industry. UTHR outperforms 99.43% of its industry peers.
- In the last couple of years the Operating Margin of UTHR has grown nicely.
- UTHR has a better Gross Margin (88.59%) than 90.53% of its industry peers.
- In the last couple of years the Gross Margin of UTHR has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 48.65% | ||
| PM (TTM) | 40.65% | ||
| GM | 88.59% |
OM growth 3Y7.2%
OM growth 5Y2.85%
PM growth 3Y13.74%
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-0.58%
2. Health
2.1 Basic Checks
- UTHR has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- The number of shares outstanding for UTHR has been reduced compared to 1 year ago.
- The number of shares outstanding for UTHR has been increased compared to 5 years ago.
- The debt/assets ratio for UTHR has been reduced compared to a year ago.
2.2 Solvency
- An Altman-Z score of 19.18 indicates that UTHR is not in any danger for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 19.18, UTHR belongs to the top of the industry, outperforming 88.45% of the companies in the same industry.
- There is no outstanding debt for UTHR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 19.18 |
ROIC/WACC1.98
WACC8.75%
2.3 Liquidity
- UTHR has a Current Ratio of 6.40. This indicates that UTHR is financially healthy and has no problem in meeting its short term obligations.
- UTHR's Current ratio of 6.40 is fine compared to the rest of the industry. UTHR outperforms 65.53% of its industry peers.
- A Quick Ratio of 6.07 indicates that UTHR has no problem at all paying its short term obligations.
- With a decent Quick ratio value of 6.07, UTHR is doing good in the industry, outperforming 64.77% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.4 | ||
| Quick Ratio | 6.07 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an nice 15.90% over the past year.
- Measured over the past years, UTHR shows a quite strong growth in Earnings Per Share. The EPS has been growing by 16.88% on average per year.
- Looking at the last year, UTHR shows a quite strong growth in Revenue. The Revenue has grown by 13.50% in the last year.
- UTHR shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.71% yearly.
EPS 1Y (TTM)15.9%
EPS 3Y34.86%
EPS 5Y16.88%
EPS Q2Q%12.05%
Revenue 1Y (TTM)13.5%
Revenue growth 3Y19.52%
Revenue growth 5Y14.71%
Sales Q2Q%6.76%
3.2 Future
- The Earnings Per Share is expected to grow by 11.57% on average over the next years. This is quite good.
- Based on estimates for the next years, UTHR will show a quite strong growth in Revenue. The Revenue will grow by 11.21% on average per year.
EPS Next Y12.23%
EPS Next 2Y9.98%
EPS Next 3Y8.48%
EPS Next 5Y11.57%
Revenue Next Year11.53%
Revenue Next 2Y8.62%
Revenue Next 3Y8.84%
Revenue Next 5Y11.21%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 17.62, the valuation of UTHR can be described as rather expensive.
- Based on the Price/Earnings ratio, UTHR is valued cheaply inside the industry as 94.89% of the companies are valued more expensively.
- The average S&P500 Price/Earnings ratio is at 27.47. UTHR is valued slightly cheaper when compared to this.
- A Price/Forward Earnings ratio of 15.63 indicates a correct valuation of UTHR.
- 95.45% of the companies in the same industry are more expensive than UTHR, based on the Price/Forward Earnings ratio.
- Compared to an average S&P500 Price/Forward Earnings ratio of 24.26, UTHR is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.62 | ||
| Fwd PE | 15.63 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of UTHR indicates a rather cheap valuation: UTHR is cheaper than 96.97% of the companies listed in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of UTHR indicates a rather cheap valuation: UTHR is cheaper than 95.83% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.93 | ||
| EV/EBITDA | 10.05 |
4.3 Compensation for Growth
- The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- UTHR has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)1.44
PEG (5Y)1.04
EPS Next 2Y9.98%
EPS Next 3Y8.48%
5. Dividend
5.1 Amount
- No dividends for UTHR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
464.93
-7.06 (-1.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-29 2025-10-29/bmo
Earnings (Next)02-24 2026-02-24/amc
Inst Owners98.84%
Inst Owner Change0.05%
Ins Owners1.84%
Ins Owner Change2.26%
Market Cap20.02B
Revenue(TTM)3.13B
Net Income(TTM)1.27B
Analysts80.95
Price Target520.16 (11.88%)
Short Float %4.99%
Short Ratio4.14
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.9%
Min EPS beat(2)-9.46%
Max EPS beat(2)-2.35%
EPS beat(4)0
Avg EPS beat(4)-4.02%
Min EPS beat(4)-9.46%
Max EPS beat(4)-0.45%
EPS beat(8)2
Avg EPS beat(8)-2.47%
EPS beat(12)5
Avg EPS beat(12)-3.15%
EPS beat(16)7
Avg EPS beat(16)-2.98%
Revenue beat(2)0
Avg Revenue beat(2)-3.23%
Min Revenue beat(2)-3.81%
Max Revenue beat(2)-2.65%
Revenue beat(4)1
Avg Revenue beat(4)-0.39%
Min Revenue beat(4)-3.81%
Max Revenue beat(4)6.71%
Revenue beat(8)5
Avg Revenue beat(8)1.56%
Revenue beat(12)7
Avg Revenue beat(12)1.27%
Revenue beat(16)9
Avg Revenue beat(16)1.26%
PT rev (1m)0%
PT rev (3m)6.2%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.55%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.63%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.48%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.06%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.62 | ||
| Fwd PE | 15.63 | ||
| P/S | 6.4 | ||
| P/FCF | 17.93 | ||
| P/OCF | 12.86 | ||
| P/B | 3.04 | ||
| P/tB | 3.09 | ||
| EV/EBITDA | 10.05 |
EPS(TTM)26.39
EY5.68%
EPS(NY)29.75
Fwd EY6.4%
FCF(TTM)25.93
FCFY5.58%
OCF(TTM)36.14
OCFY7.77%
SpS72.65
BVpS153.05
TBVpS150.34
PEG (NY)1.44
PEG (5Y)1.04
Graham Number301.46
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.3% | ||
| ROE | 19.3% | ||
| ROCE | 22.37% | ||
| ROIC | 17.33% | ||
| ROICexc | 29.21% | ||
| ROICexgc | 30.07% | ||
| OM | 48.65% | ||
| PM (TTM) | 40.65% | ||
| GM | 88.59% | ||
| FCFM | 35.69% |
ROA(3y)14%
ROA(5y)12.47%
ROE(3y)16.72%
ROE(5y)15.47%
ROIC(3y)14.96%
ROIC(5y)13.31%
ROICexc(3y)29.18%
ROICexc(5y)24.89%
ROICexgc(3y)30.03%
ROICexgc(5y)25.71%
ROCE(3y)19.31%
ROCE(5y)17.18%
ROICexgc growth 3Y23.22%
ROICexgc growth 5Y4.92%
ROICexc growth 3Y22.46%
ROICexc growth 5Y5.97%
OM growth 3Y7.2%
OM growth 5Y2.85%
PM growth 3Y13.74%
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-0.58%
F-Score8
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 533.09% | ||
| Cap/Sales | 14.06% | ||
| Interest Coverage | 81.39 | ||
| Cash Conversion | 96.99% | ||
| Profit Quality | 87.79% | ||
| Current Ratio | 6.4 | ||
| Quick Ratio | 6.07 | ||
| Altman-Z | 19.18 |
F-Score8
WACC8.75%
ROIC/WACC1.98
Cap/Depr(3y)347.88%
Cap/Depr(5y)280.91%
Cap/Sales(3y)8.54%
Cap/Sales(5y)7.36%
Profit Quality(3y)85.86%
Profit Quality(5y)98.64%
High Growth Momentum
Growth
EPS 1Y (TTM)15.9%
EPS 3Y34.86%
EPS 5Y16.88%
EPS Q2Q%12.05%
EPS Next Y12.23%
EPS Next 2Y9.98%
EPS Next 3Y8.48%
EPS Next 5Y11.57%
Revenue 1Y (TTM)13.5%
Revenue growth 3Y19.52%
Revenue growth 5Y14.71%
Sales Q2Q%6.76%
Revenue Next Year11.53%
Revenue Next 2Y8.62%
Revenue Next 3Y8.84%
Revenue Next 5Y11.21%
EBIT growth 1Y12.9%
EBIT growth 3Y28.12%
EBIT growth 5Y17.97%
EBIT Next Year20.27%
EBIT Next 3Y4.67%
EBIT Next 5Y-4.6%
FCF growth 1Y46.07%
FCF growth 3Y31.3%
FCF growth 5YN/A
OCF growth 1Y62.87%
OCF growth 3Y30.42%
OCF growth 5YN/A
UNITED THERAPEUTICS CORP / UTHR FAQ
What is the fundamental rating for UTHR stock?
ChartMill assigns a fundamental rating of 7 / 10 to UTHR.
What is the valuation status of UNITED THERAPEUTICS CORP (UTHR) stock?
ChartMill assigns a valuation rating of 6 / 10 to UNITED THERAPEUTICS CORP (UTHR). This can be considered as Fairly Valued.
Can you provide the profitability details for UNITED THERAPEUTICS CORP?
UNITED THERAPEUTICS CORP (UTHR) has a profitability rating of 9 / 10.
What are the PE and PB ratios of UNITED THERAPEUTICS CORP (UTHR) stock?
The Price/Earnings (PE) ratio for UNITED THERAPEUTICS CORP (UTHR) is 17.62 and the Price/Book (PB) ratio is 3.04.
What is the expected EPS growth for UNITED THERAPEUTICS CORP (UTHR) stock?
The Earnings per Share (EPS) of UNITED THERAPEUTICS CORP (UTHR) is expected to grow by 12.23% in the next year.